Request for Comments on USPTO Initiatives To Promote Generic Drug and Biosimilar Competition
LexBlog IP
OCTOBER 25, 2022
Patent and Trademark Office (USPTO) recently published a request for comments addressing a variety of topics related to generic drug and biosimilar competition. How would eliminating terminal disclaimers, thus prohibiting patents that are obvious variations of each other, affect patent prosecution strategies and patent quality overall?
Let's personalize your content